false
--12-31
0001979005
0001979005
2026-11-10
2026-11-10
0001979005
AFJK:OrdinarySharesParValue0.0001PerShareMember
2026-11-10
2026-11-10
0001979005
AFJK:RightsExchangeableIntoOnefifthOfOneOrdinaryShareMember
2026-11-10
2026-11-10
0001979005
AFJK:UnitsEachConsistingOfOneOrdinaryShareAndOneRightMember
2026-11-10
2026-11-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
United
States
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
November
10, 2026
Date
of Report (Date of earliest event reported)
AIMEI
HEALTH TECHNOLOGY CO., LTD
(Exact
Name of Registrant as Specified in its Charter)
| Cayman
Islands |
|
001-41880 |
|
N/A
00-0000000 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
10
East 53rd Street, Suite 3001
New
York, NY |
|
10022 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
86-13758131392
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each Class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Ordinary
Shares, par value $0.0001 per share |
|
AFJK |
|
The
Nasdaq Stock Market LLC |
| Rights,
exchangeable into one-fifth of one Ordinary Share |
|
AFJKR |
|
The
Nasdaq Stock Market LLC |
| Units,
each consisting of one Ordinary Share and one Right |
|
AFJKU |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
1.01. Entry into a Material Definitive Agreement.
Trust
Agreement Amendment
As
approved by its shareholders at the Extraordinary General Meeting (defined below), Aimei Health Technology Co., Ltd (the “Company”)
entered into a third amendment dated November 19, 2026 (the “Trust Agreement Amendment”) to the
Investment Management Trust Agreement, dated December 1, 2023, as amended (the “Trust Agreement”), with Continental
Stock Transfer & Trust Company, as trustee (“Trustee”). Pursuant to the Trust Agreement Amendment, the
period within which the Company may consummate its initial business combination is extended from up to 36 months from the date of the
Company’s initial public offering (“IPO”) (namely, December 6, 2026) to up to 48 months from the date
of the IPO (namely, December 6, 2027) (the “Extension”). The amount of funds required to be deposited into
the trust account managed by the Trustee (the “Trust Account”) for each monthly extension remains the lesser
of (i) $80,000 for all outstanding ordinary shares sold in the IPO (the “Public Shares”) and (ii) $0.033 for
each outstanding Public Share.
The
Trust Agreement Amendment is filed as Exhibit 10.1 hereto, which is incorporated herein by reference.
Item
3.03. Material Modification to Rights of Security Holders.
The
information disclosed in Item 5.07 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03 to the extent
required herein.
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Pursuant
to the results of the Extraordinary General Meeting, Article 35.2 of the Amended and Restated Articles of Association of the Company,
as in effect immediately prior to the Extraordinary General Meeting, was amended and restated to extend the date by which the Company
has to consummate a business combination from 36 months from the date of the Company’s initial public offering (namely, December
6, 2026) to 48 months from the date of the Company’s initial public offering (namely, December 6, 2027). In accordance with Cayman
Islands law, the Company will forward a copy of the special resolution approving the Article Amendment Proposal to the Cayman Islands
Registrar of Companies (in the form attached as Exhibit 3.1). Such exhibit is incorporated by reference into this Item 5.03. The information
disclosed in Item 5.07 of this Current Report on Form 8-K is incorporated by reference into this Item 5.03 to the extent required herein.
Under
Cayman Islands law, the amendment to the Articles took effect upon approval of the Article Amendment Proposal on November 10, 2026.
Item
5.07. Submission of Matters to a Vote of Security Holders.
On
November 10, 2026, the Company held its previously announced extraordinary general meeting of shareholders of the Company (the “Extraordinary
General Meeting”) virtually online at https://www.virtualshareholdermeeting.com/AFJKU2026, pursuant to due notice. The
board of directors of the Company fixed the close of business on October 2, 2026 as the record date for the determination of shareholders
entitled to notice of and to vote at the Extraordinary General Meeting or at any adjournment thereof (“Record Date”).
On the Record Date, the Company had 3,166,332 ordinary shares issued and outstanding and holders of such shares were entitled to notice
of and to vote at the Extraordinary General Meeting. At the Extraordinary General Meeting, holders of the Company’s outstanding
ordinary shares in attendance (represented in person or by proxy) voted on four proposals presented, the Article Amendment Proposal,
the Trust Agreement Amendment Proposal, the Auditor Appointment Proposal, and the Adjournment Proposal, each as described in the proxy
statement dated October 19, 2026 (the “EGM Proxy Statement”). The shareholders represented in person or by
proxy and entitled to vote at the Extraordinary General Meeting cast their votes as described below.
Capitalized
terms used but not defined herein have the meaning given to them in the EGM Proxy Statement.
Proposal
1 - Article Amendment Proposal
The
holders of the outstanding ordinary shares of the Company in attendance (represented in person or by proxy) and entitled to vote at the
Extraordinary General Meeting approved, as a special resolution, the proposal to amend and restate Article 35.2 of the Amended and Restated
Articles of Association of the Company currently in effect (the “Articles”), to extend the date by which the
Company has to consummate a business combination from 36 months from the date of the Company’s initial public offering (namely,
December 6, 2026) to 48 months from the date of the Company’s initial public offering (namely, December 6, 2027). The following
is a tabulation of the voting results:
Ordinary
shares:
| | |
Votes For | | |
Votes Against | | |
Abstentions | |
| Number of outstanding ordinary shares voted: | |
| 2,757,268 | | |
| 5,377 | | |
| 16 | |
There
were 79,881 broker non-votes with respect to the Article Amendment Proposal. Broker non-votes are counted for quorum purposes.
Proposal
2 - Trust Agreement Amendment Proposal
The
holders of the outstanding ordinary shares of the Company in attendance (represented in person or by proxy) and entitled to vote at the
Extraordinary General Meeting approved, as an ordinary resolution, the proposal to amend the Investment Management Trust Agreement dated
December 1, 2023, as amended, entered into by and between Continental Stock Transfer & Trust Company, as trustee, and the Company,
to reflect the extension of the date by which the Company has to consummate a business combination from 36 months from the date of the
Company’s initial public offering to 48 months from the date of the Company’s initial public offering. The following is a
tabulation of the voting results:
Ordinary
shares:
| | |
Votes For | | |
Votes Against | | |
Abstentions | |
| Number of outstanding ordinary shares voted: | |
| 2,757,268 | | |
| 5,377 | | |
| 16 | |
There
were 79,881 broker non-votes with respect to the Trust Agreement Amendment Proposal.
Proposal
3 - Auditor Appointment Proposal
The
holders of the outstanding ordinary shares of the Company in attendance (represented in person or by proxy) and entitled to vote at the
Extraordinary General Meeting approved, as an ordinary resolution, the engagement of MaloneBailey, LLP to serve as the Company’s
independent registered public accounting firm for the year ending December 31, 2026. The following is a tabulation of the voting results:
Ordinary
shares:
| | |
Votes For | | |
Votes Against | | |
Abstentions | |
| Number of outstanding ordinary shares voted: | |
| 2,840,119 | | |
| 1,961 | | |
| 462 | |
There
were no broker non-votes with respect to the Auditor Appointment Proposal.
Proposal
4 - Adjournment Proposal
The
holders of the outstanding ordinary shares of the Company in attendance (represented in person or by proxy) and entitled to vote at the
Extraordinary General Meeting approved the proposal to direct the chairman of the Extraordinary General Meeting to adjourn the Extraordinary
General Meeting to a later date or dates to permit further solicitation of proxies in the event that there are insufficient votes for,
or otherwise in connection with, the approval of the Article Amendment Proposal, the Trust Agreement Amendment Proposal, or the Auditor
Appointment Proposal, to be determined by the chairman of the Extraordinary General Meeting. The following is a tabulation of the voting
results:
Ordinary
shares:
| | |
Votes For | | |
Votes Against | | |
Abstentions | |
| Number of outstanding ordinary shares voted: | |
| 2,834,906 | | |
| 7,174 | | |
| 462 | |
There
were no broker non-votes with respect to the Adjournment Proposal.
Item
8.01. Other Events.
In
connection with the approval of the Article Amendment Proposal at the Extraordinary General Meeting, and as of the reporting date, holders
of 841,629 Public Shares exercised their right to redeem those shares for cash at an approximate price of $12.33 per share, for an aggregate
of approximately $10,377,384. Following the payment of the redemptions, the Trust Account will have a balance of approximately $2,450,031
and the Company will have 2,324,703 ordinary shares outstanding.
No
Offer or Solicitation
This
Current Report on Form 8-K shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or
in respect of any business combination. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of
an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation,
or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.
Forward-Looking
Statements
This
Current Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements that are not historical
facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking
statements. These forward-looking statements and factors that may cause such differences include, without limitation, uncertainties relating
to our ability to complete an initial Business Combination and other risks and uncertainties indicated from time to time in our filings
with the SEC, including under the caption “Risk Factors” in the reports we file with the SEC. The Company expressly disclaims
any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect
any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any
statement is based.
Item
9.01 Exhibits.
(d)
Exhibits.
| Exhibit
No. |
|
Description |
| 3.1 |
|
Form of Director’s Certificate certifying the special resolution passed by the Company at the Extraordinary General Meeting |
| 10.1 |
|
Third
Amendment to the Investment Management Trust Agreement, dated November 19, 2026, by and between Aimei Health Technology Co.,
Ltd and Continental Stock Transfer & Trust Company |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
November 19, 2026
| |
Aimei
Health Technology Co., Ltd |
| |
|
|
| |
By: |
/s/
Junheng Xie |
| |
Name: |
Junheng
Xie |
| |
Title: |
Chief
Executive Officer |